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Abstract Oxylipins, including eicosanoids, affect a broad
range of biological processes, such as the initiation and reso-
lution of inflammation. These compounds, also referred to as
lipid mediators, are (non-) enzymatically generated by oxida-
tion of polyunsaturated fatty acids such as arachidonic acid
(AA). A plethora of lipid mediators exist which makes the
development of generic analytical methods challenging. Here
we developed a robust and sensitive targeted analysis platform
for oxylipins and applied it in a biological setting, using high
performance liquid chromatography coupled to tandem mass
spectrometry (HPLC-MS/MS) operated in dynamic multiple
reaction monitoring (dMRM). Besides the well-described AA
metabolites, oxylipins derived from linoleic acid, dihomo-γ-
linolenic acid, α-linolenic acid, eicosapentaenoic acid and
docosahexaenoic acid were included. Our comprehensive
platform allows the quantitative evaluation of approximately
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100 oxylipins down to low nanomolar levels. Applicability of
the analytical platformwas demonstrated by analyzing plasma
samples of patients undergoing cardiac surgery. Altered levels
of some of the oxylipins, especially in certain monohydroxy
fatty acids such as 12-HETE and 12-HEPE, were observed in
samples collected before and 24 h after cardiac surgery. These
findings indicate that this generic oxylipin profiling platform
can be applied broadly to study these highly bioactive com-
pounds in relation to human disease.
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Introduction
Oxylipins are oxygenated metabolites derived from poly-
unsaturated fatty acids (PUFAs) such as arachidonic acid
(AA), linoleic acid (LA), eicosapentaenoic acid (EPA), doco-
sahexaenoic acid (DHA), and dihomo-γ-linolenic acid
(DGLA). The oxygenated 20-carbon products, collectively
referred to as eicosanoids, are the best-described lipid media-
tors. Among their many functions, these lipids are potent
inflammatory modulators and thus have been associated with
responses to cardiovascular diseases, host defense, tissue in-
jury, and surgical intervention [1–3].
Through both, enzymatic and non-enzymatic oxidation pro-
cesses, these PUFAs are transformed into a variety of oxylipins.
They can be generated from the different precursor PUFAs by
three main classes of enzymes—cyclooxygenase (COX), lip-
oxygenase (LOX), and cytochrome P450 (CYP450)—and thus
form a complex pool of bioactive components (Fig. 1). Prosta-
glandins (PG) and thromboxanes (TX) are generated via the
initial oxidation through COX pathways [4]. Prostanoids de-
rived fromAA are generally known as class 2 PGs and TXs due
to their residual double-bond number, e.g., PGE2 and TXB2.
Class 1 and 3 PGs and TX are similarly produced through the
oxidation of DGLA and EPA, respectively [5]. Leukotrienes,
likewise involved in pro-inflammatory signaling, especially in
chemotaxis of leukocytes, are generated via the LOX pathways
[4, 6]. In mammalian cells, three LOX hydroperoxidases
families exist, 5-LOX, 15-LOX, and 12-LOX, from which
5-LOX generates leukotrienes. Other LOX-dependent prod-
ucts include the mid-chain alcohols such as the AA-derived
hydroxyeicosatetraenoic acids (HETEs), as well as the LA-
derived hydroxyoctadecadienoic acids (HODEs) and EPA-
derived hydroxypentaenoic acids (HEPEs). HETEs are
known to be bioactive lipid mediators in chemotaxis and de-
granulation processes of neutrophils [7–9]. Omega-terminal
oxidation of these PUFAs by CYP450 yields additional metab-
olites such as epoxides, diols, and further HETEs. Epoxides
derived from AA are known to be associated to cardiovascular
functions, in particular acting as vasodilators of human coro-
nary arteries [10, 11]. For epoxides derived from EPA, similar
functions are evident [12]. While conversion of the epoxy fatty
acids to diols reduces their vasoactive properties, the diols
themselves appear to have distinct functions, for instance as
ligands of the peroxisome proliferator activated receptor alpha
subtype (PPARα) [13, 14].
Although several oxylipins have been allocated to regulato-
ry functions, the biological impact for many others remains
unclear. Therefore, the bioactive potential of the less well-
characterized lipids, either as unique functions or interaction
with structural analogs from different precursor PUFAs, is
likely to provide a rich source of novel insights into the regu-
lation of mammalian responses to disease and tissue injury.
Covering a wide range of these highly bioactive compounds
still remains a challenge with modern analytical techniques. As
a common approach, immunoassays are performed, either as
radioimmunoassay [15, 16], enzyme immunoassays [17], or
luminescent immunoassays [18, 19]. They are specific and
focus on one or only few compounds. Gas chromatography
coupled to mass spectrometry (GC-MS) technology provides a
sensitive methodology for a broad range of oxylipins [20].
However, to increase volatility, derivatization steps are essen-
tial. To avoid additional modifications, liquid chromatography-
mass spectrometric (LC-MS) techniques are one of the most
sensitive and specific tools to simultaneously study many anal-
ogous analytes. Numerous LC-MS/MS methods have been
described in literature for identification and quantification of
low abundant oxylipins using multiple reaction monitoring
(MRM) as an ion selective mode. Many methods focus on
certain component classes of oxylipins as for instance prosta-
glandins [21–23], non-prostanoid eicosanoids [24], COX and
LOXderived eicosanoids [25, 26], CYP450 related compounds
[27, 28], and AA derived lipid mediators including metabolites
of all three pathways [29–31]. However, the bioactive lipids of
different origins are produced within the same cascade and
cross-linked in a complex regulatory network (Fig. 1). Thus,
the complex combination of chemically and structurally related
oxylipins derived from the different PUFAs has become a
challenge in modern LC-MS/MS techniques [32–36]. The
development of a generic analytical oxylipin platform, intended
for the application to a variety of biological matrices, will
provide valuable information on metabolites derived from dif-
ferent precursor PUFAs and contribute importantly to our
knowledge on inflammation processes.
Within this work we expand these methods to include an
even broader array of prostanoids while demonstrating the
utility of dynamic multiple reaction monitoring (dMRM) mode
to focus on short retention time windows and enhance sensi-
tivity. We applied our platform to human plasma derived from
patients a day before and 24 h after cardiac surgery. Previous
studies have demonstrated involvement of eicosanoids in myo-
cardial ischemia/reperfusion injury. Arachidonic acid accumu-
lates in the reperfused heart after an ischemic period and levels
of prominent eicosanoids like PGE2, TXB2, and 6-keto-PGF1α
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change rapidly after reperfusion [37–39]. In this study, we focus
on late phase (i.e., 24 h post surgery) changes in circulating
eicosanoids and further demonstrate the applicability of this
generic LC-MS/MS platform to monitor physiological levels
of a broad range of eicosanoids and related metabolites
derived from different PUFAs in human plasma.
Material and methods
Materials
Ultra performance liquid chromatography (UPLC)-grade
acetonitrile, isopropanol, methanol, ethyl-acetate, and water
were purchased from Biosolve (the Netherlands). Gla-
cial acetic acid was from Sigma-Aldrich (St. Louis,
MO). High performance liquid chromatography
(HPLC) was performed with the Ascentis Express
C18 (2.1×150 mm, 2.7 μm) column from Sigma-
Aldrich (St. Louis, MO). Solid phase extraction (SPE)
was accomplished with Oasis HLB (60 mg/30 μm)
cartridges from Waters (Milford, MA). Deuterated and
non-deuterated oxylipin standards were purchased
either from Cayman Chemicals (Ann Arbor, MI), Bio-
mol (Plymouth Meeting, PA), or Larodan (Malmö,
Sweden). Human EDTA-plasma for method validation
was provided by Richmond Pharmacology Ltd.
(London, UK).
Fig. 1 Biosynthesis of
oxylipins derived from linoleic
acid (LA; green), dihomo-γ-
linolenic acid (DGLA; red),
arachidonic acid (AA; blue),
eicosapentaenoic acid (EPA;
orange), docosahexaenoic acid
(DHA; yellow), and α-linolenic
acid (ALA; purple) via lipoxy-
genase (LOX), cyclooxygenase
(COX), and cytochrome P450
(CYP450) pathways; PLA2:
phospholipase A2; metabolites
(bold marked) are included in
the oxylipin library of the de-
scribed analytical platform
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Patient population
Oxylipin profiling was performed on EDTA-plasma derived
from patients before and after cardiac surgery. The study
protocols were approved by the local ethics committee, and
informed consent was obtained from each patient. All
patients were male and with good left ventricular function
and 55 (±5.4) years of age with a BMI of 27.1 (±4.1)kg/m2.
As patients develop a state of inflammation upon cardiac
surgery, these patients provided a well controlled sample set
to monitor levels of oxylipins in their function as bioactive
lipid mediators after cardiac surgery. During cardiac arrest
(myocardial ischemia), cardiac surgery was executed with
use of a heart–lung machine. After 124.2 (±21.9)min of
ischemia, the aortic cross-clamp was removed to restore
cardiac blood flow (i.e., reperfusion).
To avoid any effects of heparin, such as increased levels
of oxylipins by heparin induced phopholipase A2 activity,
described in literature [40, 41], samples collected during the
period in which heparin was administered to the patient
were not used. Heparin administrated in conjunction with
heart–lung machine use is neutralized by protamine sulfate,
administrated in the operating room directly after the surgi-
cal intervention. Based on our own confirmation of a
heparin-dependent elevation in circulating oxylipins (data
not shown) and their response to protamine sulfate treat-
ment, we chose to analyze samples taken the day before
surgery (no heparin administrated to the patient) and 24 h
after reperfusion of the heart, when no influence of heparin
could be detected. All baseline and 24 h post-reperfusion
samples were taken at the same moment during the day,
between 12:00 noon and 2:00 p.m., to reduce the potential
impact of circadian rhythm-dependent cycling which can
affect several oxylipins. While they show a morning peak,
the concentrations reduce during the day [42–44].
Oxylipin extraction from human blood plasma
The samples (10 mL) were taken the day before surgery by
venipuncture (baseline) from the brachial vein and 24 h after
reperfusion from the radial artery. All samples were collect-
ed in pre-cooled tubes containing EDTA (BD Vacutainer,
Plymouth, UK) and placed on melting ice immediately.
Blood samples were centrifuged (1.550×g, 10 min, 4 °C)
and the derived plasma supernatant was re-centrifuged
(10.000×g, 4 min, 4 °C) to obtain leukocyte and thrombo-
cyte poor plasma. Aliquots were stored at −80 °C until
extraction. The extraction was performed as described pre-
viously [36]. For oxylipin analysis 250 μL aliquots were
taken. After thawing on ice, the samples were treated im-
mediately with antioxidants (0.2 mg BHT/EDTA) and
spiked with 5 μL of internal standards (ISTDs) of a concen-
tration of 1,000 nM, resulting in 100 nM after reconstitution
which is within the linear range of the method. Compound
extraction was performed with solid phase extraction using
Oasis HLB (60 mg/30 μm). Oxylipins were eluted with
2 mL ethyl acetate after wetting the cartridge with 0.5 mL
methanol. In contrast to Shearer and coauthors [36], the
eluent was reduced under nitrogen stream instead under
vacuum. The dried extract was subsequently reconstituted
in 50 μL solution of methanol and acetonitrile (1:1) con-
taining 100 nM 1-cyclohexyluriedo-3-dodecanoic acid
(CUDA) as a quality marker for the analysis. Afterwards,
the extract was filtered by centrifugation using Amicon
Ultrafree-MC Durapore PVDF filter (pore-size 0.1 μM;
Millipore, Bedford, MA).
Liquid chromatography and mass spectrometry
Samples were analyzed by liquid chromatography (Agilent
1260, San Jose, CA, USA) coupled to electrospray ionization
on a triple quadrupole mass spectrometer (Agilent 6460, San
Jose, CA, USA). For analysis 5 μL of the extract was injected.
The auto sampler was cooled at 10 °C. Chromatographic
separation was achieved on an Ascentis Express (2.1×150
mm, 2.7 μm particles; Sigma-Aldrich Supelco) column using
a flow rate of 0.35 mL/min at 40 °C during a 26 min gradient
(0–3.5 min from 15 % B to 33 % B, 3.5–5.5 min B to 38 %,
5–7 min to 42 % B, 7–9 min to 48 % B, 9–15 min to 65 % B,
15–17 min to 75 % B, 17–18.5 min to 85 % B, 18.5–19.5 min
to 95 % B, from 19.5 to 21 min to 15 % B, 21–26 min 15 %
B), while using the solvents A, 0.1 % acetic acid, and B, 90:10
v/v acetonitril/isopropanol. Electrospray ionization was per-
formed in the negative ion mode using N2 at a pressure of
35 psi for the nebulizer with a flow of 10 L/min and a
temperature of 300 °C, respectively. The sheath gas tempera-
ture was 350 °C with a flow rate of 11 L/min. The capillary
was set at 3,500 V and the nozzle voltage was 1,000 V.
To detect the individual oxylipins, MRM in negative ion
mode was performed with individually optimized fragmentor
voltage and collision energies (Optimizer application, Mass-
Hunter, Agilent). MRM transitions were achieved by flow
injection of pure standards and the optimizer application and
were compared to literature when available for the certain
compounds. The detailed list of MRM transitions can be
found in the Electronic Supplementary Material Table S-1.
Instead of defining certain time segments, with fixed dwell
times per compound, dynamic MRM was used, assuring
optimal dwell time and sufficient data points per peak.
Data preprocessing
Peak determination and peak area integration was performed
with Mass Hunter Quan (Agilent, Version B.04.00) while
auto-integration was manually inspected and corrected if
necessary. The obtained peak areas of targets were corrected
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by appropriate internal standards (ISTD) and calculated
response ratios were used throughout the analysis.
Method validation
The method validation was performed as in-house 3-day pro-
tocol to determine linearity, LOD and LOQ, inter- and intra-day
variation, reproducibility, matrix effect, and recovery for all
compounds. Compound stability was not included in this val-
idation, but is being performed in a dedicated experiment and
currently ongoing (stability period up to 48 weeks at −80 °C
without antioxidants). Preliminary data on this stability exper-
iment showed no significant degradation over a period of
6 month (data not shown). We spiked pooled EDTA-plasma
(Richmond Pharmacology, London, UK) with the purchased
standard compounds in different concentrations varying from a
minimum of 2 nM up to 558 nM in 8 levels (corresponding to
levels of 3 to 1,260 pg; Electronic Supplementary Material
Table S-2) to determine the linearity. Each calibration level
was extracted twice and injected three times. Calibration curves
were calculated by linear regression with 1/S2 weighing. Not all
levels were included for each analyte. Only if a response was
measured, i.e., for many analytes the low levels were not
included. Furthermore, if the endogenous concentration was
relatively high compared to the additionally spiked concentra-
tion, there is no difference in measured response when going to
the next spiked level. For the calibration line, only levels were
included if a significant response increase occurred from level
to level. The responses were compared by means of t tests
going from low to high level. For example, if the tests show
no significant differences between level C0 compared to level
C1 and C1 versus C2 but a significantly higher response for C3
compared to C2 than the measurements for C0 and C1were not
included in the calibration line and C2 was the lowest included
level. LOD and LOQ were determined by signal to noise ratio
(S/N) higher 3 and 10, respectively. For the calculation of
possible batch-to-batch effect, we compared three different
concentrations, lower level (C3), middle (C5), and high level
(C7). Three different batches were prepared at three following
days. To determine the recovery of the oxylipins, we spiked the
pooled plasma with 11 deuterated ISTDs prior to the extraction
step and in parallel after the last step of the extraction proce-
dure. The labeled standards are non-endogenous and can be
distinguished from endogenous ones with mass spectrometry.
The 11 chosen ISTDs were considered to be representative for
the different compound classes. Recovery was calculated as
Areaspiked before/Areaspiked after.
Results and discussion
A robust and sensitive quantitative method for profiling
oxylipins such as eicosanoids and related lipid mediators
biosynthesized from AA and other PUFAs was developed.
As the majority of these compounds are present in plasma at
low concentrations, their detection and quantification re-
quire methods with high sensitivity. Our LC-MS/MS meth-
od, employing dynamic MRM (dMRM), allows the
evaluation of more than 100 oxylipins in a targeted ap-
proach (Fig. 2). The performance of dMRM allows the triple
TXBs LTs
DiolsPGs Tetranor-PGs
Monohydroxy
Fatty Acids
Epoxides
Hydroperoxides
Fig. 2 LC-MS/MS chromatogram of 104 oxylipins performed on a triple quadrupole employing dynamic MRM in negative mode (exp. details; see
the “Materials and methods” section and Table 2)
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quadrupole system to be focused directly on the expected
analyte retention time (tR) with a defined detection window
instead of user-defined time segments to capture groups of
closely eluting compounds. Allowing a constant cycle time
for each transition, the dMRM procedure improves peak
symmetry. Moreover, since transitions are only monitored
in the defined detection windows in contrast to the whole
time period of a standard MRM time segment, the rate of
false positive detection (i.e., peak misidentification) is di-
minished. This is especially relevant for oxylipin families,
which encompasses many isomeric and isobaric com-
pounds. Furthermore, sensitivity can be enhanced since
optimal dwell times can be achieved by reducing overlap-
ping ion transitions [45].
For each compound, optimal transitions were deter-
mined to assure optimal peak detection (Electronic Supple-
mentary Material Fig. S-1 and Table S-1). In the case of co-
eluting metabolites, compound specific precursor ions and
their corresponding fragment ions allowed separation for
selective detection and quantification of those compounds
(Fig. 3). For instance, for 2,3-dinor-11ß-PGF2α (m/z 325→
145) and 6-keto-PGF1α (m/z 369 → 163), both elute at tR
7.89 min. Additional pairs were PGF1α/9,10,13-TriHOME;
13,14-dihydro-15-keto-PGF1α/1a,1b-dihomo-PGF2α;
8,15-DiHETE/12,13-DiHODE; 5,6-DiHETE/20-HETE;
13-HpODE/17(18)-EpETE; and 9-KODE/14(15)-EpETE
(Fig. 3). For co-eluting isobars a unique fragment ion was
chosen, as for 12-HETE (m/z 319→ 179) and 8-HETE (m/z
319 → 115), both eluting at tR 19.24 (Fig. 3). However,
some critical pairs could not be separated spectrally with
the current method. Those compounds were 19-hydroxy-
PGE2/20-hydroxy-PGE2, 19-hydroxy-PGF2α/20-hydroxy-
PGF2α, as well as LTB4/12-epi LTB4 and 6-trans-LTB4/6-
trans-12-epi LTB4. For detection and data evaluation, these
compounds are therefore reported as combined amounts.
For the hydroperoxides (HpETEs and HpODEs), we per-
ceived a loss of an H2O molecule during ionization leading
to [M–H–H2O]
−. The water loss, especially for the hydro-
peroxides from AA, was also described previously [46].
Taken together, by employing dMRM and the detection
of specified transitions in our HPLC-MS/MS approach, we
were able to detect more than 100 different oxylipins.
Method validation
Validation measurements were performed using pooled
EDTA-plasma as a sample matrix. Linearity, sensitivity
(LOD and LOQ), reproducibility, matrix effect, and recov-
ery were determined (Table 1 and Electronic Supplementary
Material Table S-3).
Linearity and sensitivity Thematrix samples (pooled plasma)
were spiked with academic standards (eight concentrations).
We determined the linearity, LOD, and LOQ of each com-
pound (104 targets). For the majority of the analytes, the R2
ranged from 0.991 to 0.999, followed by 0.981–0.99 for 26 %
and >0.9 for 17 % (Electronic Supplementary Material Table
S-3). The range of LOQwas between 0.3 and 102 nM. For the
majority of the targets (81 %), the LOQwas below 10 nM, for
56% it was below 3 nM. Relatively high LOQswere observed
for 5,6-Lipoxin A4 with values higher than 80 nM.
Reproducibility To examine reproducibility, intra- and inter-
batch variability was assessed for all academic standards. A
total of three batches were processed. In each batch dupli-
cate extractions and triplicate injections were performed. In
Table 1, oxylipins detected in human plasma are shown. The
reproducibility values for all compounds are summarized in
the Electronic Supplementary Material (Table S-3). For
intra-batch effects (precision), the highest RSD value above
the LOD was taken. For the oxylipins, the RSD values
ranged from 4 % up to 15 % with exceptions for 20-HETE
(41 %), 9,12,13-TriHOME (32 %), and 16(17)-EpDPE
(21 %). The batch-to-batch effects were higher for the low
concentration level, compared to the high concentration
level for the oxylipin platform. As problematic compounds
with batch-to-batch effects higher than 50 %, 15-keto
PGF1α, PGK2, Hepoxilin A3, 5,6-Lipoxin A4, LTE4, 5-
HpETE, 12-HpETE, 15-HpETE, 9-HpODE, 13-HpODE,
and PGF3α need to be noted (Electronic Supplementary
Material Table S-3).
Matrix effect Matrix effect was evaluated by comparing
extracts of spiked matrix with extracts of spiked blank matrix
using water as blank matrix sample. Due to irreversible ad-
sorption during SPE of the standards from water as compared
to plasma, extreme low values (approximately 10 %) of the
expected values were observed, prohibiting this approach to
calculate matrix effects. Since water is not suitable as blank
matrix, matrix variation tests are recommended before appli-
cation to the various matrices. Although no matrix effect was
determined, final concentrations were not effected as the
calibration lines were made in matrix as well.
Recovery For the recovery calculations, a set of deuterated
ISTDs was used to prevent endogenous influences. Therefore,
the standards were spiked either before or after the extraction
and ratios of the peak areas were calculated. Recoveries
ranged from 84 % (±4.4) to 45 % (±5.8), depending on the
compound (Fig. 4). The recoveries for monohydroxy com-
pounds (i.e., HETEs and HODEs) were lower than those of
more polar prostaglandins and thromboxane. For (d3) LTE4,
the recovery was lower than 60 %. In contrast to the other
selected oxylipins, LTE4 contains a cysteinyl group, and like
LTDs and LTCs, it belongs to the cysteinyl leukotriens. While
recoveries differed between chemical class, inter-batch
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Fig. 3 LC-MS/MS extracted
chromatograms of co-eluting
oxylipins acquired by dynamic
MRM. Retention time and spe-
cific MRM transitions are
shown for each oxylipin
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Table 1 Validation results of, in study samples, detected oxylipins
Compound name Retention time R2 LOD [nM] LOQ [nM] Intra-batch effect
RSD [%]
Batch-to-batch effect
RSD [%]
Arachidonic acid
TXB2 9.24 0.995 0.3 1.0 <7 13–22
PGF2α 9.96 0.998 0.9 2.9 <10 4–15
PGE2 10.23 0.999 0.2 0.6 <13 4–20
11β-PGE2 10.40 0.998 0.9 3.1 <8 3–19
13,14-dihydro PGF2α 10.79 0.990 11.4 38.2 <8 12–26
14,15-DiHETrE 15.65 0.997 0.3 1.0 <6 2–21
11,12-DiHETrE 16.23 0.993 0.5 1.7 <12 6–21
8,9-DiHETrE 16.71 0.993 0.3 1.0 <15 10–17
5,6-DiHETrE 17.34 0.994 0.4 1.2 <9 7–21
15-HETE 18.58 0.982 0.2 0.8 <11 6–18
11-HETE 18.97 0.987 0.3 0.9 <9 4–21
12-HETE 19.24 0.986 0.2 0.6 <9 4–17
8-HETE 19.25 0.990 1.4 4.7 <8 8–21
5-HETE 19.69 0.988 0.2 0.6 <11 14–20
Linoleic acid
9,12,13-TriHOME 9.83 0.946 0.2 0.8 <32 9–16
9,10,13-TriHOME 9.96 0.953 0.5 1.8 <10 10–17
12,13-DiHOME 14.80 0.975 0.3 1.0 <4 3–6
9,10-DiHOME 15.18 0.981 0.5 1.8 <8 5–9
13-HODE 18.12 0.940 4.2 13.9 <9 7–16
9-HODE 18.25 0.942 0.2 0.5 <7 7–22
13-HpODE 18.60 0.939 3.5 11.8 <6 23–72
13-KODE 18.70 0.978 0.7 2.4 <14 8–48
9-HpODE 18.71 0.953 8.7 29.1 <7 29–72
9-KODE 19.09 0.951 3.2 10.8 <11 10–30
12(13)-EpOME 20.08 0.964 2.5 8.4 <7 14–39
9(10)-EpOME 20.27 0.932 0.6 1.9 <11 10–38
Dihomo-gamma-linolenic acid
PGF1α 9.94 0.996 0.8 2.5 <14 5–12
15(S)-HETrE 19.41 0.988 0.5 1.7 <11 7–21
Alpha-linolenic acid
9-HOTrE 16.57 0.967 0.3 1.1 <7 5–23
Eicosapentaenoic acid
17,18-DiHETE 14.01 0.990 4.7 15.5 <11 8–26
14,15-DiHETE 14.49 0.993 0.8 2.7 <13 11–22
15(S)-HEPE 17.28 0.983 0.9 3.1 <13 11–19
12(S)-HEPE 17.67 0.985 0.3 0.9 <12 6–23
5(S)-HEPE 18.05 0.983 0.1 0.3 <12 8–24
Docosahexaenoic acid
19,20-DiHDPA 15.60 0.991 1.7 5.7 <11 6–30
19(20)-EpDPE 19.93 0.988 1.2 4.0 <12 6–18
The table gives an overview about the acquired validation parameter linearity (R2 ), sensitivity (LOD/LOQ) and reproducibility (precision and
batch-to-batch effect). Validation data were achieved in pooled EDTA-plasma
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reproducibility was acceptable with RSD values between
4.3 % and 9.6 %, except for (d3) LTE4 and (d6) 20-HETE
with more than 10 % (10.3 % and 12.9 %).
In summary, the analytical oxylipin platform developed
here is characterized by high sensitivity reaching nanomolar
levels, linearity with acceptable R2, good reproducibility,
and high coverage of oxylipin compounds.
Detection of oxylipins in human plasma
Applying the oxylipin profiling platform to human EDTA-
plasma, we were able to detect 36 oxylipins derived from 6
different PUFAs (Table 1). The majority of oxylipins
detected in plasma are assigned to AA and LA, followed
by metabolites derived from EPA, DHA, DGLA, and ALA.
All these metabolites are biosynthesized via the three enzy-
matic COX, LOX, and CYP450 pathways. As the most
prominent metabolites of the COX pathway, prostaglandins
PGE2 and PGF2α as well as the thromboxane B2, derived
from AA, were detected. Furthermore, the prostaglandin F1α
was detected, which is generated from DGLA as precursor,
while no EPA derived 3 series prostanes were detected. The
hydroxylated products of AA, LA, ALA, and DGLA repre-
sent a large target group in this analytical profile and are
regulated by diverse sources in biological systems. For
example, hydroxy lipids are generated in the LOX pathways
(see Fig. 1), the COX pathways (e.g., LA metabolism by
COX to HODEs [47, 48], as well as through non-enzymatic
interactions of the PUFAs with reactive oxygen [49]. In
addition, both epoxide and diol products from the CYP
epoxygenase-dependent metabolism of AA (e.g., 11,12-
DiHETrE), LA (e.g., 9(10)-EpOME), EPA (e.g., 14,15-
DiHETE), and DHA (19(20)-EpDPE and 19,20-DiHPDA)
were detected (Table 2).
In the previous studies, it was demonstrated that a variety
of oxylipins could be detected in human plasma [35, 36, 50,
51]. Our findings are in agreement with these reported
profiles. In our hands though, remarkable variations were
observed in profiles and actual concentration levels between
plasma pools of different origin, sample handling, and stor-
age (data not shown).
Comparing patient oxylipin concentrations before sur-
gery revealed substantial variation between patients. Previ-
ous studies have shown that even when individuals have the
same physical condition, gender, and health, their basal
oxylipin concentrations can differ remarkably [52]. Never-
theless, we observed similar patterns in abundance and
relationships between certain compounds (Fig. 5). For in-
stance, the levels of PGF2α and its metabolite 13,14-dihy-
dro-PGF2α were consistently higher in their relative
abundance than levels of PGE2 and its epimer 11ß-PGE2.
The levels of TXB2, the stable hydrolysis product of TXA2,
were lower compared to the prostaglandins and thus indicate
lower levels of TXA2. For CYP450 related compounds of
the AA-pathway, 14,15-DiHETrE and 11,12-DiHETrE were
found to be present at higher levels than 8,9-DiHETrE and
5,6-DiHETrE. Epoxides of the AA-pathway were below the
detection limit and thus not detected in these samples. Also
for the LA-pathway related oxylipins, a similarity in the
basic abundance of the metabolites was observed. Although
the epoxides and furthermore hydroperoxides originating
from LA were detected above detection levels, they were
less abundant compared to their subsequent derivatives.
Alterations in oxylipin profiles during cardiac surgery
All included patients were gender and age matched, and
underwent the same surgical procedure. Twenty-four
hours after surgery, the levels of CRP and IL-6 were
significantly increased indicating an inflammatory re-
sponse after the surgery (Fig. 6). The metabolic state of
the AA pathway before and after cardiac surgery was
monitored for each patient (Electronic Supplementary
Material Fig. 2). Despite substantial inter-patient variation
in oxylipin concentrations both before and after surgery,
several consistent changes in the oxylipin profiles were
observed. For the HETEs, compounds biosynthesized via
the LOX pathway, a dramatic increase was visible, in
particular for 12-HETE and 5-HETE (Fig. 7). The LOX
products 12-HETE and 5-HETE are involved in chemo-
taxis of neutrophils [9, 53–55]. Activation and accumula-
tion of neutrophils play key roles in inflammatory
processes during ischemia–reperfusion injury [53, 56,
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Fig. 4 Recovery of deuterated, non-endogenous oxylipins; the recov-
ery is shown as percentage value; the compounds are arranged by their
polarity, with the more polar ones on the left hand side
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57]. Due to its chemotactic properties, 12-HETE has been
linked to healing processes during inflammation [58, 59].
Analysis of oxylipin profiles after abdominal aortic aneu-
rism repair also showed high levels of 12-HETE in
plasma 24 h after surgery for the group of patients which
were in the resolution phase of inflammation [60].
Another 5-LOX generated compound LTB4 also pro-
motes the chemotaxis of neutrophils [4, 6, 53, 56, 57,
Table 2 Oxylipins detected in human plasma
LA DGLA AA ALA EPA DHA
Prostanoids/thromboids
PGF1a TXB2
PGF2a
PGE2
11b-PGE2
13,14-dihydro-PGF2a
Diols
12,13-DiHOME 14,15-DiHETrE 17,18-DiHETE 19,20-DiHDPA
9,10-DiHOME 11,12-DiHETrE 14,15-DiHETE
8,9-DiHETrE
5,6-DiHETrE
5,15-DiHETEa
8,15-DiHETEa
Epoxides
12(13)-EpOME 14(15)-EpETrEa 19(20)-EpDPE
9(10)-EpOME 11(12)-EpETrEa 16(17)-EpDPEa
8(9)-EpETrEa
5(6)-EpETrEa
Alcohols
12-HETE 12-HEPE
9-HODE 5-HETE 9-HOTE 5-HEPE
13-HODE 15-HETrE 15-HETE 15-HEPE 17-HDoHEa
8-HETE
9-HETEa
20-HETEa
11-HETE
12-HHTrEa
Ketones
13-KODE 15-KETEa
9-KODE 5-KETEa
Hydroperoxides
13-HpODE 15-HpETEa
9-HpODE 5-HpETEa
Triols
9,12,13-TriHOME
9,10,13-TriHOME
Compounds are assigned to their specific precursor fatty acid
a Oxylipin metabolite was detected in pooled EDTA-plasma, but not in EDTA-plasma of the study samples
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Fig. 7 The pairplot demonstrates the abundance of the two monohy-
droxy fatty acids 12-HETE and 5-HETE at baseline levels before the
surgery (T0) and 24 h after the surgery (T24) of the patients (n05);
both oxylipins are enzymatically generated via lipoxygenase (12-LOX
and 5-LOX, respectively) from arachidonic acid as precursor PUFA;
dotted lines represent the limit of quantification
Fig. 6 CRP- and IL-6 levels
before and after surgery; (a)
CRP levels (n05), after surgery
the CRP levels increased dra-
matically; (b) IL-6 levels (n05),
also for IL-6 levels a significant
increment after surgery was
observed
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Fig. 5 Baseline level of oxylipins detected in patients undergoing
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two pathways, (A) metabolites derived from arachidonic acid (AA)
and (B) metabolites generated from linoleic acid (LA); each graph
shows the relative abundance of oxylipins, plotted as relative response
ratios (obtained abundance corrected by appropriated ISTDs)
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61–64]. Interestingly, no LTB4 was detected in plasma while
5-HETE was one of the metabolites increased after surgery.
Besides the high levels of 12-HETE and 5-HETE, increases
in the analogous EPA metabolites 12-HEPE and 5-HEPE
were observed (Fig. 8). The metabolites 12-HEPE and 5-
HEPE are produced via the LOX pathway, but with EPA as
precursor fatty acid. EPA derived LOX products can provide
chemotactic activities, but are less potent than products of
AA [62, 65].
For COX derived metabolites, such as the prostaglandins
and thromboxanes, no significant changes were observed in
human plasma (Electronic Supplementary Material Fig. 2).
In previous studies on ischemia/reperfusion of the heart,
metabolites of the COX pathway, especially PGE2, TXB2,
and 6-keto-PGF1α, were significantly increased in heart
perfusates [37]. A similar observation was made for
CYP450 related compounds such as DiHETrEs. At the
24 h time point sampled here, only minor fluctuations were
observed, suggesting acute COX-dependent responses had
subsided by this time.
Our findings indicate that the analytical platform developed
here allows the detection of consistent alterations in oxylipin
profiles, even within a small patient population (n05).
Conclusions
We developed an LC-MS/MS method to detect oxylipins. Our
target library comprises an expanded set of more than 100
compounds biosynthesized from six different PUFAs in one
LC-MS/MS analysis. These targets include a wide array of
both pro- and anti-inflammatory lipid mediators. Our oxylipin
profiling platform was developed and validated for human
plasma on a triple quadrupole mass spectrometer using multi-
ple reaction monitoring operated in a dynamic MRM mode to
guarantee high sensitivity, i.e., down to nM levels. This tech-
nology allows the sensitive detection of co-eluting compounds
and isomers as well as several isobaric compounds by detect-
ing specific transitions for each analyte with optimal dwell
times in defined time windows. Our method was demonstrated
on patients undergoing cardiac surgery and was able to detect
one third of our target library in human plasma. The metabo-
lites 12-HETE and 5-HETE, known to be related to cardiac
surgery and healing processes, were consistently increased
after cardiac surgery. In addition, an increase of similar mono-
hydroxy metabolites derived from EPAwas observed. In con-
clusion, the analytical platform developed here allows specific
and sensitive quantitative assessment of more than 100 oxy-
lipins andmay have wider applications in studies on the role of
these highly bioactive metabolites in human diseases. The
successful application of the developed method to this biolog-
ical study implies that the developed platform can be used
broadly to profile these highly bioactive compounds.
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